Asia Pacific Diabetic Neuropathy Treatment Market Size & Outlook
Asia Pacific diabetic neuropathy treatment market, 2018-2030 (US$M)
Related Markets
Asia Pacific diabetic neuropathy treatment market highlights
- The Asia Pacific diabetic neuropathy treatment market generated a revenue of USD 915.4 million in 2023.
- The market is expected to grow at a CAGR of 10.1% from 2024 to 2030.
- In terms of segment, peripheral neuropathy was the largest revenue generating disorder type in 2023.
- Autonomic Neuropathy is the most lucrative disorder type segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 915.4 million |
| Market revenue in 2030 | USD 1,800.6 million |
| Growth rate | 10.1% (CAGR from 2023 to 2030) |
| Largest segment | Peripheral neuropathy |
| Fastest growing segment | Autonomic Neuropathy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy |
| Key market players worldwide | Abbott Laboratories, Eli Lilly and Co, Pfizer Inc, Janssen Pharmaceuticals, Lupin, Astellas Pharma Inc, Glenmark Pharmaceuticals, Boehringer Ingelheim, Novartis AG ADR |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 21.1% of the global diabetic neuropathy treatment market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,800.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Diabetic Neuropathy Treatment Market Scope
Diabetic Neuropathy Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific diabetic neuropathy treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to diabetic neuropathy treatment market will help companies and investors design strategic landscapes.
Peripheral neuropathy was the largest segment with a revenue share of 63.09% in 2023. Horizon Databook has segmented the Asia Pacific diabetic neuropathy treatment market based on peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Diabetic Neuropathy Treatment Disorder Type Outlook (Revenue, USD Million, 2018-2030)
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
- Asia Pacific Diabetic Neuropathy Treatment Drug Class Outlook (Revenue, USD Million, 2018-2030)
- Capsaicin
- Opioid
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Antidepressants
- Other Drug Class
- Asia Pacific Diabetic Neuropathy Treatment Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacies
- Retail Pharmacies
- Others Distribution Channel
Reasons to subscribe to Asia Pacific diabetic neuropathy treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific diabetic neuropathy treatment market databook
-
Our clientele includes a mix of diabetic neuropathy treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific diabetic neuropathy treatment market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific diabetic neuropathy treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific diabetic neuropathy treatment market report size, by country, 2018-2030 (US$M)
Asia Pacific Diabetic Neuropathy Treatment Market Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
